Trinitrobenzenesulfonic acid (TNBS) and
dextran sodium sulfate (DSS) are commonly used to induce experimental murine
ulcerative colitis (UC). Our recent study has demonstrated that a novel
andrographolide derivative,
AL-1, ameliorated TNBS-induced
colitis in mice. However, the effect of
AL-1 on DSS-induced murine
colitis and the underlying mechanisms are yet unknown. In the present study, we aimed to investigate the therapeutic potential of
AL-1 against DSS-induced UC in mice and to define its mechanisms of action.
Oral administration of
AL-1 attenuated
body weight loss, reduced colon length shortening, lowered the disease activity index score, and alleviated colon histological damage.
AL-1 significantly inhibited
myeloperoxidase activity and suppressed immune inflammatory responses in colonic tissues. Moreover,
AL-1 reversed DSS-altered expression of inflammatory
cytokines in DSS-induced
colitis mice. Importantly, the efficacy of 45 mg/kg of
AL-1 was higher than that of 100 mg/kg of the positive control drugs
5-aminosalicylic acid and
mesalazine.
AL-1 decreased
lipopolysaccharide-induced generation of
reactive oxygen species and
nitric oxide in cultured macrophages in vitro; it also reversed the altered expression of inflammatory
cytokines. In both in vivo and in vitro studies, Western blot analysis revealed that
AL-1 reduced the expression of phosphorylated NF-κB p65 and IκBα, downregulated the expression of iNOS and COX-2, and attenuated the expression of phosphorylated
p38 mitogen-activated protein kinase (MAPK), ERK, and JNK. In conclusion,
AL-1 alleviated DSS-induced murine
colitis by inhibiting activation of the NF-κB and MAPK signaling pathways. Our data suggest that
AL-1 could be a potential new treatment for UC.